fda compounding semaglutide news Compound versions of GLP-1 drugs for weight loss halted by The FDA's Decision to Ban

Unfortunately, most regain two-thirds of their lost weight within a year as well as worsening of metabolic health indicators (Mozaffarian et al., 2025

GLP-1 RAs exert immunomodulatory properties through peripheral and central pathways

This isnt complex, but it does require attention to detail and willingness to learn proper technique

Retatrutide is an investigational triple agonist peptide currently under clinical development, targeting the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors simultaneously

Many experience minimal effects

A custom protocol based on lab results will almost always outperform a one-size-fits-all formula